Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 12Cytarabine 12Azacitidine 10Decitabine 8Daunorubicin 7Cyclophosphamide 7Busulfan 6fludarabine phosphate 5Idarubicin 5Gemtuzumab 5Thiotepa 3Stem Cell Transplantation 3Filgrastim 3Cyclosporine 3vosaroxin 2fludarabine 2Whole-Body Irradiation 2Tretinoin 2Sorafenib 2Radiotherapy 2Methylprednisolone 2Methotrexate 2Melphalan 2Injections 2Etoposide 2Cladribine 2CPX-351 2Antilymphocyte Serum 2Abatacept 2vedolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia, Myeloid, Acute × cedazuridine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡